Blood Screening Market Size, Share & Trends Analysis Report By Technology (Nucleic Acid Amplification Test, ELISA, Western Blotting), By Product (Reagent, Instrument), By Region, And Segment Forecasts, 2025 - 2030
Blood Screening Market Growth & Trends
The global blood screening market size is expected to reach USD 6.62 billion by 2030, registering a CAGR of 11.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process to mandates testing all donated blood for several viruses.
Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). The result of all these assays must be negative for blood donation.
Technological developments increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.
Blood Screening Market Report Highlights
Nucleic acid amplification tests (NAT) dominated the market and accounted for the largest revenue share of 41.2% in 2024 attributed to the increasing prevalence of infectious diseases, such as HIV and hepatitis, necessitating accurate and rapid testing methods that NAATs provide.
Next Generation Sequencing (NGS) is expected to grow at a CAGR of 16.5% over the forecast period. The technology has revolutionized genomic analysis by significantly reducing sequencing costs while improving accuracy.
Reagents led the market and accounted for the largest revenue share of 73.4% in 2024. Reagents are essential components in diagnostic tests, providing the necessary chemical, biological, or immunological substances to elicit specific reactions for accurate results.
Instruments are expected to grow at the fastest CAGR of 10.8% over the forecast period, owing to technological advancements and increasing demand for effective diagnostic solutions.
North America blood screening market dominated the global market and accounted for the largest revenue share of 38.4% in 2024 attributed to advanced healthcare infrastructure and a strong emphasis on patient safety.
Please note The report will be delivered in 2-3 business days upon order notification.